The U.S. is quickly approaching a record number of wild birds and poultry affected by avian influenza, announced the U.S. Centers for Disease Control and Prevention (CDC) last week.
Since early 2022, more than 49 million birds have either died due to a Eurasian H5N1 avian virus infection or have been culled due to exposure to infected birds.
As of November 7, 2022, this news is nearing the largest bird flu outbreak in the U.S. that occurred in 2015.
Even so, the number of states affected in 2022 is already more than double the number of states involved in 2015.
U.S. Approaches Bird Flu Infection Record
International Visitors Must Continue Verifying COVID-19 Vaccination Status
The U.S. Transportation Security Administration (TSA) Acting Executive Assistant Administrator of Operations Support Austin Gould recently signed a new Security Directive that continues requiring certain non-residents entering the U.S. to present proof of COVID-19 vaccination.
TSA Security Directive 1544-21-03A applies to non-US citizens traveling on an airline effective November 9, 2022, and remains in effect until January 8, 2023.
International airlines must confirm that each Covered Individual has the following:
Second, Third COVID-19 Vaccine May Up Relapse in Glomerular Disease
Absolute increase in 30-day relapse risk associated with the second or third vaccine dose is small
COVID-19 Tied to Higher Risk for New, Worsening Bladder Symptoms
Symptomatic infection tied to three times greater risk for developing new or worsening overactive bladder symptoms
COVID-19 mRNA Vaccines Tied to Higher Risk for Myocarditis, Pericarditis
Authors say benefits of vaccination still outweigh risks, but some individuals should be aware of their higher risk
Europe Approves Single-dose RSV Option for Infants
The European Commission became the first regulatory body to approve preventing respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season with passive immunization.
AstraZeneca and Sanofi’s Beyfortus® (nirsevimab) approval in the European Union was announced on November 4, 2022.
However, the actual availability date in Europe was not disclosed today.
Pfizer Study Reveals Big Rise in Immunity From COVID-19 Booster
FDA says findings affirm its decision to approve the booster without human testing based on experience with a similarly tweaked vaccine
Age-Adjusted Rate of Alcohol-Induced Deaths Up From 2019 to 2020
Rates of alcohol-induced deaths in 2020 increased with age, peaking for those aged 55 to 64 years
mRNA-Based Influenza and COVID-19 Combo Vaccine Candidate Launches Study
Global leaders in vaccine innovation today announced the advancement of an mRNA-based vaccine candidate preventing both influenza and COVID-19 to a Phase 1 clinical trial.
The Pfizer Inc. and BioNTech SE vaccine candidate aims to address these severe respiratory diseases with one vaccine.
The vaccine candidate combines Pfizer's quadrivalent modRNA-based influenza vaccine candidate, qIRV (22/23), which is currently in Phase 3 clinical development, and Pfizer and BioNTech's authorized Omicron-adapted bivalent COVID-19 BNT162b2 (Original/Omicron BA.4/BA.5) vaccine.